Scholarlink

Background <p>There is a group of patients with conductive hearing loss (CHL), mixed hearing loss (MHL), and single-sided deafness (SSD) who do not benefit from middle ear surgery or conventional hearing aids and are not candidates for cochlear implantation. Bone conduction hearing implantation (BCHI) serves as the definitive solution for this cohort. While percutaneous designs offer direct stimulation, they are frequently plagued by long-term soft-tissue complications. Active piezoelectric BCHI systems have been developed to overcome these challenges and the acoustic limitations of passive transcutaneous systems.</p> Aims &amp; objectives <p>This study evaluates the clinical, surgical, and audiological outcomes of active piezoelectric BCHI and compares these results with legacy percutaneous systems.</p> Materials &amp; methods <p>The study included all patients who underwent active piezoelectric BCHI at our center and completed one year of post-implantation follow-up before prior to completion of the study. A total of 27 patients were enrolled for this study, including 11 children and 16 adults. All were implanted unilaterally with the Cochlear Osia-2 active piezoelectric BCHI system. Outcomes were assessed by measuring preoperative and postoperative hearing thresholds, speech recognition thresholds (SRT) in both quiet and noisy environments. A detailed analysis of postoperative surgical complications was done over an average follow-up duration of 12 months. The results were compared with the known complication rates of traditional percutaneous systems.</p> Results <p>It was noted that subjects with active piezoelectric BCHI showed a substantial improvement in hearing thresholds with a mean gain of 36.25 dB HL across the speech frequencies. Additionally, a statistically significant improvement in speech in noise was also noted with a p-value of &lt; 0.05. Most importantly, this study noted no skin overgrowth or infection, along with 0% major surgical complications, which is in great contrast with the 59% morbidity rate of percutaneous systems.</p> Conclusion <p>Active piezoelectric BCHI is a reliable, low-maintenance treatment option for CHL, MHL, and SSD. This technology significantly enhances the quality of life for patients who are not candidates for traditional hearing solutions or cochlear implants.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcome of active piezoelectric bone conduction implants: our experience at a tertiary care centre of Western India

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月29日

查看全文
  • Lokanath Sahoo,
  • Vishal Gaurav,
  • Amit Gaur,
  • Nitu Singh,
  • Rahul Kurkure,
  • Kiran Upadhyay,
  • Vikas Gupta,
  • Anandita Gupta,
  • Vivek Kumar Singh,
  • Krushnendu Sundar Sahoo

摘要

Background

There is a group of patients with conductive hearing loss (CHL), mixed hearing loss (MHL), and single-sided deafness (SSD) who do not benefit from middle ear surgery or conventional hearing aids and are not candidates for cochlear implantation. Bone conduction hearing implantation (BCHI) serves as the definitive solution for this cohort. While percutaneous designs offer direct stimulation, they are frequently plagued by long-term soft-tissue complications. Active piezoelectric BCHI systems have been developed to overcome these challenges and the acoustic limitations of passive transcutaneous systems.

Aims & objectives

This study evaluates the clinical, surgical, and audiological outcomes of active piezoelectric BCHI and compares these results with legacy percutaneous systems.

Materials & methods

The study included all patients who underwent active piezoelectric BCHI at our center and completed one year of post-implantation follow-up before prior to completion of the study. A total of 27 patients were enrolled for this study, including 11 children and 16 adults. All were implanted unilaterally with the Cochlear Osia-2 active piezoelectric BCHI system. Outcomes were assessed by measuring preoperative and postoperative hearing thresholds, speech recognition thresholds (SRT) in both quiet and noisy environments. A detailed analysis of postoperative surgical complications was done over an average follow-up duration of 12 months. The results were compared with the known complication rates of traditional percutaneous systems.

Results

It was noted that subjects with active piezoelectric BCHI showed a substantial improvement in hearing thresholds with a mean gain of 36.25 dB HL across the speech frequencies. Additionally, a statistically significant improvement in speech in noise was also noted with a p-value of < 0.05. Most importantly, this study noted no skin overgrowth or infection, along with 0% major surgical complications, which is in great contrast with the 59% morbidity rate of percutaneous systems.

Conclusion

Active piezoelectric BCHI is a reliable, low-maintenance treatment option for CHL, MHL, and SSD. This technology significantly enhances the quality of life for patients who are not candidates for traditional hearing solutions or cochlear implants.